<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" id="jah310323" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Am Heart Assoc</journal-id><journal-id journal-id-type="iso-abbrev">J Am Heart Assoc</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)2047-9980</journal-id><journal-id journal-id-type="publisher-id">JAH3</journal-id><journal-id journal-id-type="hwp">ahaoa</journal-id><journal-title-group><journal-title>Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease</journal-title></journal-title-group><issn pub-type="epub">2047-9980</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39575723</article-id><article-id pub-id-type="pmc">PMC11681577</article-id>
<article-id pub-id-type="doi">10.1161/JAHA.124.036799</article-id><article-id pub-id-type="publisher-id">JAH310323</article-id><article-id pub-id-type="other">JAHA/2024/036799-T</article-id><article-categories><subj-group subj-group-type="overline"><subject>Original Research</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Research</subject><subj-group subj-group-type="heading"><subject>Stroke</subject></subj-group></subj-group></article-categories><title-group><article-title>Mortality Risk in Patients With Cardiac Complications Following Ischemic Stroke: A Report From the <styled-content style="fixed-case" toggle="no">Virtual International Stroke Trials Archive</styled-content>
</article-title><alt-title alt-title-type="right-running-head">Mortality Risk in SHS</alt-title><alt-title alt-title-type="left-running-head">Ishiguchi et&#x000a0;al</alt-title></title-group><contrib-group><contrib id="jah310323-cr-0001" contrib-type="author"><name><surname>Ishiguchi</surname><given-names>Hironori</given-names></name><degrees>MD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-4597-7862</contrib-id><xref rid="jah310323-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="jah310323-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="jah310323-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="jah310323-cr-0002" contrib-type="author"><name><surname>Huang</surname><given-names>Bi</given-names></name><degrees>MD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1763-8452</contrib-id><xref rid="jah310323-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="jah310323-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="jah310323-cr-0003" contrib-type="author"><name><surname>El&#x02010;Bouri</surname><given-names>Wahbi K.</given-names></name><degrees>PhD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-2732-5927</contrib-id><xref rid="jah310323-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="jah310323-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="jah310323-cr-0004" contrib-type="author"><name><surname>Dawson</surname><given-names>Jesse</given-names></name><degrees>MD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-7532-2475</contrib-id><xref rid="jah310323-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="jah310323-cr-0005" contrib-type="author"><name><surname>Lip</surname><given-names>Gregory Y. H.</given-names></name><degrees>MD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-7566-1626</contrib-id><xref rid="jah310323-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="jah310323-aff-0005" ref-type="aff">
<sup>5</sup>
</xref><xref rid="jah310323-note-0001" ref-type="author-notes">
<sup>*</sup>
</xref></contrib><contrib id="jah310323-cr-0006" contrib-type="author" corresp="yes"><name><surname>Abdul&#x02010;Rahim</surname><given-names>Azmil H.</given-names></name><degrees>MD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1318-4027</contrib-id><xref rid="jah310323-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="jah310323-aff-0003" ref-type="aff">
<sup>3</sup>
</xref><xref rid="jah310323-aff-0006" ref-type="aff">
<sup>6</sup>
</xref><xref rid="jah310323-note-0001" ref-type="author-notes">
<sup>*</sup>
</xref><address><email>azmil.abdul-rahim@liverpool.ac.uk</email></address></contrib><contrib id="jah310323-cr-0007" contrib-type="author"><collab collab-type="authors">for the VISTA Collaborators<contrib-group><contrib id="jah310323-cr-0008" contrib-type="author"><name><surname>Alexandrov</surname><given-names>A.</given-names></name><xref rid="jah310323-cr-0007" ref-type="contrib"/></contrib><contrib id="jah310323-cr-0009" contrib-type="author"><name><surname>Bath</surname><given-names>P. M.</given-names></name><xref rid="jah310323-cr-0007" ref-type="contrib"/></contrib><contrib id="jah310323-cr-0010" contrib-type="author"><name><surname>Bluhmki</surname><given-names>E.</given-names></name><xref rid="jah310323-cr-0007" ref-type="contrib"/></contrib><contrib id="jah310323-cr-0011" contrib-type="author"><name><surname>Bornstein</surname><given-names>N.</given-names></name><xref rid="jah310323-cr-0007" ref-type="contrib"/></contrib><contrib id="jah310323-cr-0012" contrib-type="author"><name><surname>Chen</surname><given-names>C.</given-names></name><xref rid="jah310323-cr-0007" ref-type="contrib"/></contrib><contrib id="jah310323-cr-0013" contrib-type="author"><name><surname>Claesson</surname><given-names>L.</given-names></name><xref rid="jah310323-cr-0007" ref-type="contrib"/></contrib><contrib id="jah310323-cr-0014" contrib-type="author"><name><surname>Curram</surname><given-names>J.</given-names></name><xref rid="jah310323-cr-0007" ref-type="contrib"/></contrib><contrib id="jah310323-cr-0015" contrib-type="author"><name><surname>Davis</surname><given-names>S. M.</given-names></name><xref rid="jah310323-cr-0007" ref-type="contrib"/></contrib><contrib id="jah310323-cr-0016" contrib-type="author"><name><surname>Diener</surname><given-names>H&#x02010;C.</given-names></name><xref rid="jah310323-cr-0007" ref-type="contrib"/></contrib><contrib id="jah310323-cr-0017" contrib-type="author"><name><surname>Donnan</surname><given-names>G.</given-names></name><xref rid="jah310323-cr-0007" ref-type="contrib"/></contrib><contrib id="jah310323-cr-0018" contrib-type="author"><name><surname>Fisher</surname><given-names>M.</given-names></name><xref rid="jah310323-cr-0007" ref-type="contrib"/></contrib><contrib id="jah310323-cr-0019" contrib-type="author"><name><surname>Ginsberg</surname><given-names>M.</given-names></name><xref rid="jah310323-cr-0007" ref-type="contrib"/></contrib><contrib id="jah310323-cr-0020" contrib-type="author"><name><surname>Gregson</surname><given-names>B.</given-names></name><xref rid="jah310323-cr-0007" ref-type="contrib"/></contrib><contrib id="jah310323-cr-0021" contrib-type="author"><name><surname>Grotta</surname><given-names>J.</given-names></name><xref rid="jah310323-cr-0007" ref-type="contrib"/></contrib><contrib id="jah310323-cr-0022" contrib-type="author"><name><surname>Hacke</surname><given-names>W.</given-names></name><xref rid="jah310323-cr-0007" ref-type="contrib"/></contrib><contrib id="jah310323-cr-0023" contrib-type="author"><name><surname>Hennerici</surname><given-names>M. G.</given-names></name><xref rid="jah310323-cr-0007" ref-type="contrib"/></contrib><contrib id="jah310323-cr-0024" contrib-type="author"><name><surname>Hommel</surname><given-names>M.</given-names></name><xref rid="jah310323-cr-0007" ref-type="contrib"/></contrib><contrib id="jah310323-cr-0025" contrib-type="author"><name><surname>Kaste</surname><given-names>M.</given-names></name><xref rid="jah310323-cr-0007" ref-type="contrib"/></contrib><contrib id="jah310323-cr-0026" contrib-type="author"><name><surname>Lyden</surname><given-names>P.</given-names></name><xref rid="jah310323-cr-0007" ref-type="contrib"/></contrib><contrib id="jah310323-cr-0027" contrib-type="author"><name><surname>Marler</surname><given-names>J.</given-names></name><xref rid="jah310323-cr-0007" ref-type="contrib"/></contrib><contrib id="jah310323-cr-0028" contrib-type="author"><name><surname>Muir</surname><given-names>K.</given-names></name><xref rid="jah310323-cr-0007" ref-type="contrib"/></contrib><contrib id="jah310323-cr-0029" contrib-type="author"><name><surname>Roffe</surname><given-names>C.</given-names></name><xref rid="jah310323-cr-0007" ref-type="contrib"/></contrib><contrib id="jah310323-cr-0030" contrib-type="author"><name><surname>Sacco</surname><given-names>R.</given-names></name><xref rid="jah310323-cr-0007" ref-type="contrib"/></contrib><contrib id="jah310323-cr-0031" contrib-type="author"><name><surname>Teal</surname><given-names>P.</given-names></name><xref rid="jah310323-cr-0007" ref-type="contrib"/></contrib><contrib id="jah310323-cr-0032" contrib-type="author"><name><surname>Venketasubramanian</surname><given-names>N.</given-names></name><xref rid="jah310323-cr-0007" ref-type="contrib"/></contrib><contrib id="jah310323-cr-0033" contrib-type="author"><name><surname>Wahlgren</surname><given-names>N. G.</given-names></name><xref rid="jah310323-cr-0007" ref-type="contrib"/></contrib><contrib id="jah310323-cr-0034" contrib-type="author"><name><surname>Warach</surname><given-names>S.</given-names></name><xref rid="jah310323-cr-0007" ref-type="contrib"/></contrib></contrib-group>
</collab><xref rid="jah310323-note-0002" ref-type="author-notes">
<sup>
<sup>&#x02020;</sup>
</sup>
</xref></contrib></contrib-group><aff id="jah310323-aff-0001">
<label>
<sup>1</sup>
</label>
<institution>Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart &#x00026; Chest Hospital</institution>
<city>Liverpool</city>
<country country="GB">UK</country>
</aff><aff id="jah310323-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Division of Cardiology, Department of Medicine and Clinical Science</named-content>
<institution>Yamaguchi University Graduate School of Medicine</institution>
<city>Ube</city>
<country country="JP">Japan</country>
</aff><aff id="jah310323-aff-0003">
<label>
<sup>3</sup>
</label>
<named-content content-type="organisation-division">Department of Cardiovascular and Metabolic Medicine</named-content>
<institution>Institute of Life Course and Medical Sciences, University of Liverpool</institution>
<city>Liverpool</city>
<country country="GB">UK</country>
</aff><aff id="jah310323-aff-0004">
<label>
<sup>4</sup>
</label>
<named-content content-type="organisation-division">School of Cardiovascular and Metabolic Health</named-content>
<institution>College of Medical, Veterinary &#x00026; Life Sciences, University of Glasgow</institution>
<city>Glasgow</city>
<country country="GB">UK</country>
</aff><aff id="jah310323-aff-0005">
<label>
<sup>5</sup>
</label>
<named-content content-type="organisation-division">Danish Centre for Health Services Research, Department of Clinical Medicine</named-content>
<institution>Aalborg University</institution>
<city>Aalborg</city>
<country country="DK">Denmark</country>
</aff><aff id="jah310323-aff-0006">
<label>
<sup>6</sup>
</label>
<named-content content-type="organisation-division">Stroke Division, Department Medicine for Older People</named-content>
<institution>Mersey and West Lancashire Teaching Hospitals NHS Trust</institution>
<city>Prescot</city>
<country country="GB">UK</country>
</aff><author-notes><corresp id="correspondenceTo">
<label>*</label>
Correspondence to: Azmil H. Abdul&#x02010;Rahim, MD, University of Liverpool, Liverpool Centre for Cardiovascular Science, 6 West Derby Street, Liverpool, G51 4TF UK. Email: <email>azmil.abdul-rahim@liverpool.ac.uk</email>
<break/>
</corresp><fn id="jah310323-note-0001"><label>*</label><p>G. Y. H. Lip and A. H. Abdul&#x02010;Rahim are co&#x02010;senior authors.</p></fn><fn id="jah310323-note-0002"><label>
<sup>&#x02020;</sup>
</label><p>A complete list of the VISTA collaborators can be found in the appendix at the end of the article.</p></fn></author-notes><pub-date pub-type="epub"><day>22</day><month>11</month><year>2024</year></pub-date><pub-date pub-type="collection"><day>03</day><month>12</month><year>2024</year></pub-date><volume>13</volume><issue seq="340">23</issue><issue-id pub-id-type="doi">10.1002/jah3.v13.23</issue-id><elocation-id>e036799</elocation-id><history>
<date date-type="received"><day>18</day><month>9</month><year>2024</year></date>
<date date-type="accepted"><day>08</day><month>10</month><year>2024</year></date>
</history><permissions><!--Copyright &#x000a9; 2024 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell--><copyright-statement content-type="article-copyright">&#x000a9; 2024 The Author(s). Published on behalf of the American Heart Association, Inc., by Wiley.</copyright-statement><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="file:JAH3-13-e036799.pdf"/><abstract><sec id="jah310323-sec-0001"><title>Background</title><p>Cardiac complications may occur in patients following ischemic stroke (stroke&#x02010;heart syndrome [SHS]). We investigated the mortality risk in patients with SHS and across the SHS manifestations.</p></sec><sec id="jah310323-sec-0002"><title>Methods and Results</title><p>Data were sought from the VISTA (Virtual International Stroke Trials Archive), an international repository of clinical trials data. We reviewed relevant adverse events and classified patients into 2 cohorts based on the incidence of SHS. The SHS was defined as developing any cardiac complications within 30&#x02009;days following stroke. Using Cox proportional hazards models, we evaluated the temporal risk dynamics of 90&#x02010;day death associated with the day of SHS onset. We also compared the risk of 90&#x02010;day death across SHS manifestations, using multivariate analysis. Among 15&#x02009;054 patients with ischemic stroke (mean age, 69&#x000b1;12&#x02009;years; 55% men), 1787 (11.8% [95% CI, 11.3&#x02013;12.3]) developed SHS. The median onset time for SHS was 2 (interquartile range, 1&#x02013;4) days. The most prevalent manifestation was other arrhythmia/ECG abnormalities, with the incidence rate of 6.5% (95% CI, 6.1&#x02013;6.9). Patients who developed SHS between 10 and 30&#x02009;days following stroke had significantly higher risks of death compared with those with SHS within the first 0 to 3&#x02009;days (adjusted hazard ratio, 1.84 [95% CI, 1.36&#x02013;2.49]).</p><p>In the multivariate&#x02010;adjusted analysis, SHS manifested as acute myocardial injury/myocardial injury, heart failure/left ventricular dysfunction, and atrial fibrillation/flutter were associated with the highest risk of death within 90&#x02009;days after stroke across SHS manifestations excluding cardiorespiratory arrest.</p></sec><sec id="jah310323-sec-0003"><title>Conclusions</title><p>SHS is associated with a high risk of death, with a greater risk observed with delayed SHS onset.</p></sec></abstract><abstract abstract-type="graphical"><p>
<boxed-text position="anchor" content-type="graphic" id="jah310323-blkfxd-0002"><graphic xlink:href="JAH3-13-e036799-g004.jpg" position="anchor" id="jats-graphic-1"/></boxed-text>
</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="jah310323-kwd-0001">ischemic stroke</kwd><kwd id="jah310323-kwd-0002">death</kwd><kwd id="jah310323-kwd-0003">stroke&#x02010;heart syndrome</kwd></kwd-group><kwd-group kwd-group-type="subject-categories"><title>Subject Categories</title><kwd>Ischemic Stroke</kwd></kwd-group><counts><fig-count count="5"/><table-count count="3"/><page-count count="9"/><word-count count="6000"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>03 December 2024</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.5.1 mode:remove_FC converted:03.12.2024</meta-value></custom-meta></custom-meta-group></article-meta><notes><fn-group id="jah310323-ntgp-0001"><fn id="jah310323-note-0003"><p>This manuscript was sent to Jose R. Romero, MD, Associate Editor, for review by expert referees, editorial decision, and final disposition.</p></fn><fn id="jah310323-note-0004"><p>Supplemental Material is available at <ext-link xlink:href="https://www.ahajournals.org/doi/suppl/10.1161/JAHA.124.036799" ext-link-type="uri">https://www.ahajournals.org/doi/suppl/10.1161/JAHA.124.036799</ext-link>
</p></fn><fn id="jah310323-note-0005"><p>For Sources of Funding and Disclosures, see page 8.</p></fn></fn-group></notes></front><body id="jah310323-body-0001"><def-list list-content="abbreviations" id="jah310323-dl-0001"><title>Nonstandard Abbreviations and Acronyms</title><def-item><term id="jah310323-li-0001">AFL</term><def id="jah310323-li-0002"><p>atrial flutter</p></def></def-item><def-item><term id="jah310323-li-0003">AIS</term><def id="jah310323-li-0004"><p>acute ischemic stroke</p></def></def-item><def-item><term id="jah310323-li-0005">CRA</term><def id="jah310323-li-0006"><p>cardiorespiratory arrest</p></def></def-item><def-item><term id="jah310323-li-0007">SHS</term><def id="jah310323-li-0008"><p>stroke&#x02010;heart syndrome</p></def></def-item><def-item><term id="jah310323-li-0009">VISTA</term><def id="jah310323-li-0010"><p>Virtual International Stroke Trials Archive</p></def></def-item></def-list><p>
<boxed-text position="anchor" content-type="box" id="jah310323-blkfxd-0001"><caption><title>Clinical Perspective</title></caption><sec id="jah310323-sec-0006"><title>What Is New?</title><p>
<list list-type="bullet" id="jah310323-list-0001"><list-item id="jah310323-li-0011"><p>Although the incidence of stroke&#x02010;heart syndrome peaked within the first 3&#x02009;days after stroke, the mortality risk increased with later stroke&#x02010;heart syndrome onset.</p></list-item><list-item id="jah310323-li-0012"><p>Among stroke&#x02010;heart syndrome manifestations, excluding cardiorespiratory arrest, acute coronary syndrome/myocardial injury, heart failure/left ventricular dysfunction, and atrial fibrillation/flutter were independently associated with 90&#x02010;day poststroke death.</p></list-item></list>
</p></sec><sec id="jah310323-sec-0007"><title>What Are the Clinical Implications?</title><p>
<list list-type="bullet" id="jah310323-list-0002"><list-item id="jah310323-li-0013"><p>Our study emphasizes the importance of early detection and intervention in stroke&#x02010;heart syndrome due to the increasing mortality risk with delayed onset.</p></list-item><list-item id="jah310323-li-0014"><p>We also highlight the significant impact of acute coronary syndrome/myocardial injury, heart failure/left ventricular dysfunction, and atrial fibrillation/flutter on the mortality rate, underscoring the need for clinicians to closely monitor and manage these complications.</p></list-item></list>
</p></sec></boxed-text>
</p><p>The management of acute ischemic stroke (AIS) remains a major cause of death and morbidity, despite recent advances in therapeutic strategies.<xref rid="jah310323-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref>, <xref rid="jah310323-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref> Recent research has shown that &#x02248;20% of patients with AIS developed cardiac complications, adversely affecting their prognosis in both the short and long term.<xref rid="jah310323-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref>, <xref rid="jah310323-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref>, <xref rid="jah310323-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref>
</p><p>The concept of &#x0201c;stroke&#x02010;heart syndrome&#x0201d; (SHS) encapsulates the cardiac complications following AIS, characterized by the emergence of new heart conditions or the exacerbation of preexisting cardiac diseases within 30&#x02009;days after AIS.<xref rid="jah310323-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref> SHS manifestations include acute myocardial infarction; acute myocardial injury; heart failure; systolic dysfunction, including Takotsubo syndrome; arrhythmias, including ECG abnormalities and atrial fibrillation (AF); and sudden cardiac death.<xref rid="jah310323-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref>, <xref rid="jah310323-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref> The underlying mechanisms of SHS are thought to be autonomic disturbances, neurohormonal malfunctions, and neuroinflammation, stemming from the disrupted brain&#x02013;heart interaction following cerebral injury from the acute stroke.<xref rid="jah310323-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref>, <xref rid="jah310323-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref>, <xref rid="jah310323-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref>
</p><p>Although research has highlighted the adverse effects of SHS, the time course of its incidence and its prognostic implications during the acute phase of AIS remain incompletely understood.<xref rid="jah310323-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref>, <xref rid="jah310323-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref> Evidence suggests that the onset of SHS and its certain manifestations typically peak within a few days following AIS onset.<xref rid="jah310323-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref>, <xref rid="jah310323-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref>, <xref rid="jah310323-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref> Nevertheless, it is still unclear whether this peak in SHS development is directly associated with an increased mortality risk. This uncertainty highlights the need to explore the temporal dynamics of mortality risk relative to the timing of SHS onset. Moreover, while individual studies have documented the detrimental impacts of each SHS manifestation, a detailed comparative analysis among these different manifestations is yet to be undertaken.</p><p>We aimed to explore the temporal risk dynamics of death associated with the timing of SHS onset and to compare the impact of various manifestations of SHS on outcomes, using adjudicated clinical events in randomized trials.</p><sec sec-type="methods" id="jah310323-sec-0008"><title>Methods</title><sec id="jah310323-sec-0009"><title>Data Resource</title><p>We conducted a retrospective analysis on individual patient data, pooled from randomized clinical trials, available within the VISTA (Virtual International Stroke Trials Archive<xref rid="jah310323-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref>; <ext-link xlink:href="https://www.virtualtrialsarchives.org/vista/" ext-link-type="uri">https://www.virtualtrialsarchives.org/vista/</ext-link>). VISTA is a collaborative registry that collates and provides access to completed acute stroke trials' data (from year 1998 to 2010), anonymized in relation to patient and trial identity, for novel exploratory analyses.<xref rid="jah310323-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref> VISTA has institutional ethical approval (University of Glasgow UK, College of Medical Veterinary and Life Sciences' ethics committee) for the use of fully anonymized data for novel research purposes. Informed consent was not sought for the present study because it uses pooled, anonymized data from a clinical trial resource. Anonymized patient&#x02010;level data from VISTA are available upon reasonable request through its online platform. It is worth noting that VISTA data do not include trials of thrombolysis therapy, per se, although thrombolysis was commonly used as standard therapy, where appropriate. All patients with stroke were treated as per institutional practice and stroke guidelines acceptable at the point of trial conduct.<xref rid="jah310323-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref> The conduct and reporting of our analysis are in accordance with the Strengthening the Reporting of Observational Studies in Epidemiology guidelines for cohort studies.<xref rid="jah310323-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref>
</p><p>We selected patients with ischemic stroke who had been randomized to receive placebo or any drug now known to possess no confirmed action on stroke outcome. We included patients for whom we had baseline demographics and outcome information: individual components of the baseline National Institutes of Health Stroke Scale score, age, sex, comorbidities, occurrence of adverse events, serious adverse events, and death by 90&#x02009;days. The starting point for death was set as the onset of stroke.</p></sec><sec id="jah310323-sec-0010"><title>Study Design</title><p>We evaluated the incidence of SHS and each of its manifestations within our cohort. We identified patients with SHS, that is, patients who developed at least 1 of the following manifestations within 30&#x02009;days following stroke: acute coronary syndrome (ACS; including acute myocardial infarction and unstable angina pectoris)/myocardial injury (mainly termed as <italic toggle="yes">myocardial enzyme elevation</italic>), heart failure (HF)/left ventricular (LV) dysfunction, AF/atrial flutter (AFL), other arrhythmia/ECG abnormalities (ie, QTc prolongation), and cardiorespiratory arrest (CRA). We also assessed the temporal risk dynamics for the 90&#x02010;day mortality rate associated with the timing of SHS onset and its various manifestations. Subsequently, we conducted a comparative analysis of the impact on 90&#x02010;day mortality risk across different SHS manifestations, adjusting for a range of confounders. It is important to note that CRA was excluded from this analysis due to its direct association with an elevated mortality risk.</p></sec><sec id="jah310323-sec-0011"><title>Data Collection</title><p>Two authors (H.I. and B.H.) independently reviewed and identified terms describing adverse events associated with SHS in each patient. Events classified under nondefinitive categories, such as &#x0201c;possible&#x0201d; or &#x0201c;probable&#x0201d; diagnoses, were excluded from the analysis. The identified terms were cross&#x02010;checked for accuracy and consistency between the reviewers.</p></sec><sec id="jah310323-sec-0012"><title>Statistical Analysis</title><p>Variables with normal distributions were presented as mean&#x000b1;SD, and those with nonnormal distributions as medians with interquartile ranges. The Mann&#x02013;Whitney <italic toggle="yes">U</italic> test and the &#x003c7;<sup>2</sup> test were used for comparing continuous and categorical variables, respectively. We calculated incidence rates with 95% CIs for the entire period and during 3 specific intervals (&#x02264;3&#x02009;days, &#x0003e;3 to &#x02264;10&#x02009;days, and &#x0003e;10 to 30&#x02009;days). The risk of death within 90&#x02009;days was estimated using hazard ratios (HRs) with 95% CIs.</p><p>To illustrate how the hazard of death varied with the timing of the initial cardiac events, we plotted cubic spline curves for each SHS manifestation, adjusting HRs for age, sex, and baseline National Institutes of Health Stroke Scale score. We tested the overall association and nonlinearity between death and SHS, as well as each of its manifestations, using the Wald test. For the cubic spline curves, the selection of knot numbers was optimized within a range of 3 to 6, aiming for a balance between fewer knots and a lower Akaike information criterion. We also compared the adjusted HRs across the 3 intervals took the 0&#x02010; to 3&#x02010;day period as the reference.</p><p>To assess the 90&#x02010;day mortality risks associated with the various SHS manifestations, we employed multivariate Cox proportional hazard models. The observation period began on the 31st day following stroke onset. The SHS manifestations of interest were ACS/myocardial injury, HF/LV dysfunction, AF/AFL, and other arrhythmia/ECG abnormalities. We adjusted for age, sex, initial National Institutes of Health Stroke Scale score, systolic blood pressure, hemoglobin levels, creatinine levels, and comorbidities (such as hypertension, diabetes, a history of stroke, AF, HF, and coronary artery disease). Missing values were imputed using the Multivariate Imputation by Chained Equations package in R (R Foundation for Statistical Computing, Vienna, Austria). A <italic toggle="yes">P</italic> value of &#x0003c;0.05 was considered statistically significant. The analyses were conducted using R software version 4.3.0, on a virtual network computer provided by VISTA.</p></sec></sec><sec sec-type="results" id="jah310323-sec-0013"><title>Results</title><sec id="jah310323-sec-0014"><title>Patient Demographics</title><p>Figure&#x000a0;<xref rid="jah310323-fig-0001" ref-type="fig">1</xref> shows a flow diagram of the study. From a total of 17981individuals, 15&#x02009;054 eligible patients were identified. Among 6548 terms related to adverse events, 248 were categorized as cardiac events. A total of 1787 patients, corresponding to 2091 adverse events, were recognized as cases of SHS. Patient demographics are outlined in Table&#x000a0;<xref rid="jah310323-tbl-0001" ref-type="table">1</xref>. When compared with individuals without SHS, those diagnosed with SHS were older, predominantly women, exhibited more severe strokes, and had a higher prevalence of cardiovascular comorbidities.</p><fig position="float" fig-type="Figure" id="jah310323-fig-0001"><label>Figure 1</label><caption><title>Study diagram.</title><p>ACS indicates acute coronary syndrome; AF, atrial fibrillation; AFL, atrial flutter; AIS, acute ischemic stroke; CRA, cardiopulmonary arrest; HF, heart failure; ICH, intracranial hemorrhage; LV, left ventricular; SHS, stroke&#x02010;heart syndrome; and VISTA, Virtual International Stroke Trials Archive.</p></caption><graphic xlink:href="JAH3-13-e036799-g003" position="anchor" id="jats-graphic-3"/></fig><table-wrap position="float" id="jah310323-tbl-0001" content-type="Table"><label>Table 1</label><caption><p>Patient Demographics</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Patients with SHS (n=1787)</th><th align="left" rowspan="1" colspan="1">Patients without SHS (n=13&#x02009;267)</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">P</italic> value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age, y, mean&#x000b1;SD [0]</td><td align="left" rowspan="1" colspan="1">73&#x000b1;11</td><td align="left" rowspan="1" colspan="1">69&#x000b1;13</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Male, n (%) [0]</td><td align="left" rowspan="1" colspan="1">937 (52)</td><td align="left" rowspan="1" colspan="1">7416 (56)</td><td align="left" rowspan="1" colspan="1">0.006</td></tr><tr><td align="left" rowspan="1" colspan="1">History of stroke, n (%) [0.3]</td><td align="left" rowspan="1" colspan="1">448 (25)</td><td align="left" rowspan="1" colspan="1">2857 (22)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Baseline NIHSS score, mean&#x000b1;SD [25]</td><td align="left" rowspan="1" colspan="1">15&#x000b1;6</td><td align="left" rowspan="1" colspan="1">12&#x000b1;5</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Systolic blood pressure, mm&#x02009;Hg, mean&#x000b1;SD [0.6]</td><td align="left" rowspan="1" colspan="1">154&#x000b1;27</td><td align="left" rowspan="1" colspan="1">158&#x000b1;24</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Diastolic blood pressure, mm&#x02009;Hg, mean&#x000b1;SD [0.6]</td><td align="left" rowspan="1" colspan="1">81&#x000b1;17</td><td align="left" rowspan="1" colspan="1">85&#x000b1;15</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Creatinine, mg/dL, mean&#x000b1;SD [31]</td><td align="left" rowspan="1" colspan="1">1.0&#x000b1;0.36</td><td align="left" rowspan="1" colspan="1">0.95&#x000b1;0.33</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Hemoglobin, g/dL, mean&#x000b1;SD [38]</td><td align="left" rowspan="1" colspan="1">13&#x000b1;2</td><td align="left" rowspan="1" colspan="1">14&#x000b1;2</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" colspan="3" rowspan="1">Smoking [4]</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Nonsmoker, n (%)</td><td align="left" rowspan="1" colspan="1">750 (43)</td><td align="left" rowspan="1" colspan="1">5382 (42)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Former smoker, n (%)</td><td align="left" rowspan="1" colspan="1">674 (39)</td><td align="left" rowspan="1" colspan="1">4083 (32)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Current smoker, n (%)</td><td align="left" rowspan="1" colspan="1">307 (18)</td><td align="left" rowspan="1" colspan="1">3331 (26)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="4" rowspan="1">Comorbidities</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Hypertension, n (%) [5]</td><td align="left" rowspan="1" colspan="1">1286 (72)</td><td align="left" rowspan="1" colspan="1">8415 (67)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Diabetes, n (%) [0.05]</td><td align="left" rowspan="1" colspan="1">430 (24)</td><td align="left" rowspan="1" colspan="1">2807 (22)</td><td align="left" rowspan="1" colspan="1">0.006</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">History of AF, n (%) [14]</td><td align="left" rowspan="1" colspan="1">573 (33)</td><td align="left" rowspan="1" colspan="1">2591 (23)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">History of CAD, n (%) [33]</td><td align="left" rowspan="1" colspan="1">519 (38)</td><td align="left" rowspan="1" colspan="1">2200 (25)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">History of HF, n (%) [52]</td><td align="left" rowspan="1" colspan="1">259 (19)</td><td align="left" rowspan="1" colspan="1">496 (9)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr></tbody></table><table-wrap-foot id="jah310323-ntgp-0002"><fn id="jah310323-note-0006"><p>Numerical data are expressed as mean&#x000b1;SD or median (interquartile range; quartile 1&#x02013;3). Categorical data are expressed as percentages and numbers. Numbers in brackets indicate missing rate. AF indicates atrial fibrillation; BP, blood pressure; CAD, coronary artery disease; HF, heart failure; NIHSS, National Institutes of Health Stroke Scale; and SHS, stroke&#x02010;heart syndrome.</p></fn></table-wrap-foot></table-wrap></sec><sec id="jah310323-sec-0015"><title>The Incidence and Mortality Rate of SHS</title><p>Figure&#x000a0;<xref rid="jah310323-fig-0002" ref-type="fig">2A</xref> illustrates the incidence trend of SHS. The overall incidence of SHS was 11.8% (95% CI, 11.3&#x02013;12.3; Table&#x000a0;<xref rid="jah310323-tbl-0002" ref-type="table">2</xref>). The median onset time for SHS was 2 (interquartile range, 1&#x02013;4) days, with the majority of cases occurring within the first 10&#x02009;days. Among patients with SHS, 620 patients (34%) died within the 90&#x02010;day period (Table&#x000a0;<xref rid="jah310323-tbl-0002" ref-type="table">2</xref>).</p><fig position="float" fig-type="Figure" id="jah310323-fig-0002"><label>Figure 2</label><caption><title>Incidence of SHS.</title><p>
<bold>A</bold>, Incidence of SHS. <bold>B</bold>, Incidence of each manifestation. Each plot is expressed as incidence (%) with 95% CI. ACS indicates acute coronary syndrome; AF, atrial fibrillation; AFL, atrial flutter; AIS, acute ischemic stroke; CRA, cardiopulmonary arrest; HF, heart failure; LV, left ventricular; and SHS, stroke&#x02010;heart syndrome.</p></caption><graphic xlink:href="JAH3-13-e036799-g001" position="anchor" id="jats-graphic-5"/></fig><table-wrap position="float" id="jah310323-tbl-0002" content-type="Table"><label>Table 2</label><caption><p>Development Day and Incidence of SHS</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Development day, Median (quartile 1&#x02013;3)</th><th align="left" rowspan="1" colspan="1">Incidence, % (95% CI)</th><th align="left" rowspan="1" colspan="1">90&#x02010;day mortality rate, %</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">SHS</td><td align="left" rowspan="1" colspan="1">2 (1&#x02013;4)</td><td align="left" rowspan="1" colspan="1">11.8 (11.3&#x02013;12.3)</td><td align="left" rowspan="1" colspan="1">34</td></tr><tr><td align="left" rowspan="1" colspan="1">ACS/Myocardial injury</td><td align="left" rowspan="1" colspan="1">3 (2&#x02013;11)</td><td align="left" rowspan="1" colspan="1">1.0 (0.86&#x02013;1.2)</td><td align="left" rowspan="1" colspan="1">45</td></tr><tr><td align="left" rowspan="1" colspan="1">HF/LV dysfunction</td><td align="left" rowspan="1" colspan="1">4 (2&#x02013;6)</td><td align="left" rowspan="1" colspan="1">2.2 (2.0&#x02013;2.5)</td><td align="left" rowspan="1" colspan="1">56</td></tr><tr><td align="left" rowspan="1" colspan="1">AF/AFL</td><td align="left" rowspan="1" colspan="1">3 (2&#x02013;4)</td><td align="left" rowspan="1" colspan="1">6.5 (6.1&#x02013;6.9)</td><td align="left" rowspan="1" colspan="1">28</td></tr><tr><td align="left" rowspan="1" colspan="1">Other arrhythmia/ECG abnormalities</td><td align="left" rowspan="1" colspan="1">2 (1&#x02013;4)</td><td align="left" rowspan="1" colspan="1">4.2 (3.9&#x02013;4.6)</td><td align="left" rowspan="1" colspan="1">29</td></tr><tr><td align="left" rowspan="1" colspan="1">CRA</td><td align="left" rowspan="1" colspan="1">8 (2&#x02013;18)</td><td align="left" rowspan="1" colspan="1">0.55 (0.44&#x02013;0.69)</td><td align="left" rowspan="1" colspan="1">91</td></tr></tbody></table><table-wrap-foot id="jah310323-ntgp-0003"><fn id="jah310323-note-0007"><p>ACS indicates acute coronary syndrome; AF, atrial fibrillation, AFL, atrial flutter; CRA, cardiorespiratory arrest; HF, heart failure; LV, left ventricular; and SHS, stroke&#x02010;heart syndrome.</p></fn></table-wrap-foot></table-wrap></sec><sec id="jah310323-sec-0016"><title>The Incidence and Mortality Rate of Each Manifestation</title><p>Figure&#x000a0;<xref rid="jah310323-fig-0002" ref-type="fig">2B</xref> shows the incidence trends of each SHS manifestation. The most prevalent manifestation was other arrhythmia/ECG abnormalities, with an incidence rate of 6.5% (95% CI, 6.1&#x02013;6.9), followed by AF/AFL, HF/LV dysfunction, ACS/myocardial injury, and CRA (Table&#x000a0;<xref rid="jah310323-tbl-0002" ref-type="table">2</xref>). While the majority of manifestations occurred within the first 10&#x02009;days, the onset of CRA tended to occur later, at a median of 8 (interquartile range, 2&#x02013;18) days after stroke. The mortality rate remained high across all manifestations, ranging from 28% for AF/AFL to 91% for CRA (Table&#x000a0;<xref rid="jah310323-tbl-0002" ref-type="table">2</xref>).</p><p>Within the cohort identified with ACS/myocardial injury, a substantial majority, accounting for 91% (133/146 patients), were classified as having ACS. Similarly, among the patients with HF/LV dysfunction, 91% (297/325 patients), were categorized as having HF. Additionally, within the group diagnosed with AF/AFL, a significant proportion, 95% (574/606 patients), had a diagnosis with AF. Finally, of the patients with other arrhythmia/ECG abnormalities, 95% (883/934 patients) were categorized as having other arrhythmia.</p></sec><sec id="jah310323-sec-0017"><title>The Temporal Risk Dynamics for Death Based on <styled-content style="fixed-case" toggle="no">SHS</styled-content> Onset Day</title><p>Figure&#x000a0;<xref rid="jah310323-fig-0003" ref-type="fig">3</xref> showcased cubic spline curves that illustrate the 90&#x02010;day mortality risk associated with different timings of SHS onset. Based on the Akaike information criterion results, the optimal number of knots for all SHS manifestations was established at 3 (Table&#x000a0;<xref rid="jah310323-supitem-0001" ref-type="supplementary-material">S1</xref>). The overall association and linearity between the mortality rate and SHS/each manifestation are shown in Table&#x000a0;<xref rid="jah310323-supitem-0001" ref-type="supplementary-material">S2</xref>.</p><fig position="float" fig-type="Figure" id="jah310323-fig-0003"><label>Figure 3</label><caption><title>Temporal risk dynamics for dortality based on development day.</title><p>
<bold>A</bold>, SHS. <bold>B</bold>, ACS/myocardial injury. <bold>C</bold>, HF/LV dysfunction. <bold>D</bold>, AF/AFL. <bold>E</bold>, Other arrhythmia/ECG abnormalities. <bold>F</bold>, CRA. Each curve is expressed as adjusted hazard ratio with 95% CI. The dotted vertical lines on the left and right represent day 3 and day 10, respectively. ACS indicates acute coronary syndrome; AF, atrial fibrillation; AFL, atrial flutter; AIS, acute ischemic stroke; CRA, cardiopulmonary arrest; HF, heart failure; HR, hazard ratio; LV, left ventricular; and SHS, stroke&#x02010;heart syndrome.</p></caption><graphic xlink:href="JAH3-13-e036799-g005" position="anchor" id="jats-graphic-7"/></fig><p>The mortality risk increased as the onset of SHS was delayed (Figure&#x000a0;<xref rid="jah310323-fig-0003" ref-type="fig">3A</xref>). Specifically, patients who developed SHS between 10 and 30&#x02009;days following stroke onset were found to have significantly higher mortality risks compared with those who developed SHS within the initial 0 to 3&#x02009;days (Table&#x000a0;<xref rid="jah310323-tbl-0003" ref-type="table">3</xref>).</p><table-wrap position="float" id="jah310323-tbl-0003" content-type="Table"><label>Table 3</label><caption><p>Comparison of 90&#x02010;Day Mortality Risks Across the Period of Development</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Adjusted HR (95% CI)</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">P</italic> value</th></tr></thead><tbody><tr><td align="left" colspan="3" rowspan="1">SHS (N=1787)</td></tr><tr><td align="left" style="padding-left:10%" colspan="2" rowspan="1">2df test</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">&#x02264;3 d</td><td align="left" rowspan="1" colspan="1">1 (Reference)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">&#x0003e;3 to &#x02264;10 d</td><td align="left" rowspan="1" colspan="1">1.08 (0.88&#x02013;1.31)</td><td align="left" rowspan="1" colspan="1">0.461</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">&#x0003e;10 to 30 d<xref rid="jah310323-note-0009" ref-type="table-fn">*</xref>
</td><td align="left" rowspan="1" colspan="1">1.84 (1.36&#x02013;2.49)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" colspan="3" rowspan="1">ACS/Myocardial injury (N=146)</td></tr><tr><td align="left" style="padding-left:10%" colspan="2" rowspan="1">2df test</td><td align="left" rowspan="1" colspan="1">0.900</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">&#x02264;3 ds</td><td align="left" rowspan="1" colspan="1">1 (Reference)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">&#x0003e;3 to &#x02264;10 d</td><td align="left" rowspan="1" colspan="1">1.05 (0.52&#x02013;2.11)</td><td align="left" rowspan="1" colspan="1">0.875</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">&#x0003e;10 to 30 d</td><td align="left" rowspan="1" colspan="1">1.03 (0.49&#x02013;2.17)</td><td align="left" rowspan="1" colspan="1">0.973</td></tr><tr><td align="left" colspan="3" rowspan="1">HF/LV dysfunction (N=325)</td></tr><tr><td align="left" style="padding-left:10%" colspan="2" rowspan="1">2df test</td><td align="left" rowspan="1" colspan="1">0.300</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">&#x02264;3 d</td><td align="left" rowspan="1" colspan="1">1 (Reference)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">&#x0003e;3 to &#x02264;10 d</td><td align="left" rowspan="1" colspan="1">1.42 (0.96&#x02013;2.09)</td><td align="left" rowspan="1" colspan="1">0.082</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">&#x0003e;10 to 30 d</td><td align="left" rowspan="1" colspan="1">1.47 (0.79&#x02013;2.73)</td><td align="left" rowspan="1" colspan="1">0.225</td></tr><tr><td align="left" colspan="3" rowspan="1">AF/AFL (N=606)</td></tr><tr><td align="left" style="padding-left:10%" colspan="2" rowspan="1">2df test</td><td align="left" rowspan="1" colspan="1">0.300</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">&#x02264;3 d</td><td align="left" rowspan="1" colspan="1">1 (Reference)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">&#x0003e;3 to &#x02264;10 d</td><td align="left" rowspan="1" colspan="1">0.78 (0.54&#x02013;1.11)</td><td align="left" rowspan="1" colspan="1">0.210</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">&#x0003e;10 to 30 d</td><td align="left" rowspan="1" colspan="1">0.54 (0.19&#x02013;1.48)</td><td align="left" rowspan="1" colspan="1">0.477</td></tr><tr><td align="left" colspan="3" rowspan="1">Other arrhythmia/ECG abnormalities (N=934)</td></tr><tr><td align="left" style="padding-left:10%" colspan="2" rowspan="1">2df test</td><td align="left" rowspan="1" colspan="1">0.600</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">&#x02264;3 d</td><td align="left" rowspan="1" colspan="1">1 (Reference)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">&#x0003e;3 to &#x02264;10 d</td><td align="left" rowspan="1" colspan="1">1.26 (0.94&#x02013;1.66)</td><td align="left" rowspan="1" colspan="1">0.176</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">&#x0003e;10 to 30 d</td><td align="left" rowspan="1" colspan="1">1.43 (0.69&#x02013;2.93)</td><td align="left" rowspan="1" colspan="1">0.233</td></tr><tr><td align="left" colspan="3" rowspan="1">CRA (N=80)</td></tr><tr><td align="left" style="padding-left:10%" colspan="2" rowspan="1">2df test</td><td align="left" rowspan="1" colspan="1">0.007</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">&#x02264;3 d</td><td align="left" rowspan="1" colspan="1">1 (Reference)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">&#x0003e;3 to &#x02264;10 d<xref rid="jah310323-note-0009" ref-type="table-fn">*</xref>
</td><td align="left" rowspan="1" colspan="1">2.02 (1.01&#x02013;4.04)</td><td align="left" rowspan="1" colspan="1">0.046</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">&#x0003e;10 to 30 d</td><td align="left" rowspan="1" colspan="1">0.77 (0.41&#x02013;1.43)</td><td align="left" rowspan="1" colspan="1">0.411</td></tr></tbody></table><table-wrap-foot id="jah310323-ntgp-0004"><fn id="jah310323-note-0008"><p>HRs were adjusted by age, sex, and baseline NIHSS score. ACS indicates acute coronary syndrome; AF, atrial fibrillation, AFL, atrial flutter; CRA, cardiorespiratory arrest; HF, heart failure; HR, hazard ratio; LV, left ventricular; NIHSS, National Institutes of Health Stroke Scale; and SHS, stroke&#x02010;heart syndrome.</p></fn><fn id="jah310323-note-0009"><label>*</label><p>Indicates statistical significance (<italic toggle="yes">P</italic>&#x0003c;0.05).</p></fn></table-wrap-foot></table-wrap><p>As for the temporal risk dynamics for mortality rate in each manifestation, the mortality risk in ACS/myocardial injury tended to peak at around 10&#x02009;days after stroke (Figure&#x000a0;<xref rid="jah310323-fig-0003" ref-type="fig">3B</xref>). For HF/LV dysfunction and other arrhythmia/ECG abnormalities, the mortality risk tended to peak between 5 and 10&#x02009;days after stroke onset (Figure&#x000a0;<xref rid="jah310323-fig-0003" ref-type="fig">3C</xref> and <xref rid="jah310323-fig-0003" ref-type="fig">3E</xref>). The risk of death for HF/LV dysfunction was found to be higher in the &#x0003e;3 to &#x02264;10&#x02009;days following the stroke onset, compared with the initial 0&#x02010; to 3&#x02010;day period (<italic toggle="yes">P</italic>=0.082, as shown in Table&#x000a0;<xref rid="jah310323-tbl-0003" ref-type="table">3</xref>).</p><p>Conversely, the mortality risk associated with AF/AFL demonstrated a decreasing trend over time (Figure&#x000a0;<xref rid="jah310323-fig-0003" ref-type="fig">3D</xref>). This pattern suggests that the highest risk of death coincided with the onset of stroke, indicating an immediate impact on mortality rate following the stroke.</p><p>Similar to the pattern observed with ACS/myocardial injury, the mortality risk associated with CRA also reached its peak &#x02248;10&#x02009;days after the stroke onset (Figure&#x000a0;<xref rid="jah310323-fig-0003" ref-type="fig">3F</xref>, Table&#x000a0;<xref rid="jah310323-tbl-0003" ref-type="table">3</xref>). Beyond this peak period, the risk exhibited a tendency to decline, suggesting a specific window of elevated risk for patients experiencing CRA following stroke.</p></sec><sec id="jah310323-sec-0018"><title>Mortality Risks Across SHS Manifestations</title><p>The results of 90&#x02010;day mortality risk across SHS manifestations following multivariate adjustment are shown in Figure&#x000a0;<xref rid="jah310323-fig-0004" ref-type="fig">4</xref>. Among the manifestations of SHS, the development of ACS/myocardial injury, HF/LV dysfunction, and AF/AFL within 30&#x02009;days following stroke were significantly associated with death (adjusted HR, 2.39 [95% CI, 1.45&#x02013;3.96]; 1.52 [95% CI, 1.05&#x02013;2.19]; and 1.60 [95% CI, 1.18&#x02013;2.17], respectively). Additionally, other covariates such as age, baseline National Institutes of Health Stroke Scale score, creatinine level, and a history of HF and coronary artery disease were also significantly associated with an increased risk of death.</p><fig position="float" fig-type="Figure" id="jah310323-fig-0004"><label>Figure 4</label><caption><title>Mortality risks across SHS manifestations.</title><p>Each plot is expressed as adjusted hazard ratio with 95% CI. * Statistical significance (<italic toggle="yes">P</italic>&#x0003c;0.05). ACS indicates acute coronary syndrome; AF, atrial fibrillation; AFL, atrial flutter; AIS, acute ischemic stroke; BP, blood pressure; CAD, coronary artery disease; CRA, cardiopulmonary arrest; HF, heart failure; HR, hazard ratio; LV, left ventricular; NIHSS, National Institutes of Health Stroke Scale; and SHS, stroke&#x02010;heart syndrome.</p></caption><graphic xlink:href="JAH3-13-e036799-g002" position="anchor" id="jats-graphic-9"/></fig></sec></sec><sec sec-type="discussion" id="jah310323-sec-0019"><title>Discussion</title><p>The key findings of this study are as follows: First, while the occurrence of SHS predominantly peaked within the first 3&#x02009;days following stroke onset, the mortality risk tied to SHS demonstrated a gradual increase with delayed onset. Specifically, individuals developing SHS between 10 and 30&#x02009;days after stroke had substantially higher mortality risk compared with those with SHS onset within the first 3&#x02009;days after stroke. Second, certain SHS manifestations, notably HF/LV dysfunction, ACS/myocardial injury, and CRA, showed a trend of increasing mortality risk with delayed onset. In contrast, AF/AFL showed an immediate surge in mortality risk at the AIS onset, which lessened for cases emerging at later stages. Third, the development of ACS/myocardial injury, HF/LV dysfunction, and AF/AFL were significantly associated higher risk of death, compared with other SHS manifestations, excluding CRA, after multivariate adjustment.</p><sec id="jah310323-sec-0020"><title>Temporal Risk Dynamics of Death Associated With the Timing of <styled-content style="fixed-case" toggle="no">SHS</styled-content> Onset</title><p>The peak of incidence of SHS aligns with the surge in stress markers, such as catecholamines, suggesting that the acute stress responses triggered by AIS play a crucial role in the onset of SHS.<xref rid="jah310323-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref> Following this initial peak, the incidence for new cardiac events diminishes until day 14 following stroke, after which it shows a steady decline.<xref rid="jah310323-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref> Our findings reflect these observations and additionally found that mortality risk increases with delayed onset of SHS.</p><p>Several hypotheses may explain the observed outcomes. First, given that SHS involved a broad spectrum of manifestations varying in severity, it is plausible that milder manifestations occur more frequently immediately following the onset, whereas more severe conditions may manifest later. This concept is supported by our analysis, which showed a delayed peak in mortality risk for more severe manifestations such as HF/LV dysfunction and CRA. In contrast, we also infer that patients who developed SHS early on were likely predisposed to transient pathogeneses, such as arrhythmias and ECG abnormalities. These conditions are thought to be induced by self&#x02010;limiting neurogenic stressors, which are known to resolve over time.<xref rid="jah310323-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref>, <xref rid="jah310323-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref> Our hypothesis is further supported by observations indicating that the onset of other arrhythmia/ECG abnormalities preceded other clinical manifestations of SHS, with a median development time of 2&#x02009;days after stroke onset.</p><p>Second, another potential hypothesis for the observed findings is the diagnostic delay in identifying SHS during the acute phase of stroke. The diagnosis of cardiac complications can be particularly challenging in this period due to the presence of neurological deficit or coma, obscuring the clinical presentations of cardiac issues.<xref rid="jah310323-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref> Moreover, previous studies have demonstrated that certain manifestations of SHS, such as Takotsubo syndrome and acute myocardial infarction, are asymptomatic in more than half of the affected patients.<xref rid="jah310323-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref>, <xref rid="jah310323-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref>, <xref rid="jah310323-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref> The development of SHS may be considered an outcome of a &#x0201c;stress test,&#x0201d; revealing previously undiagnosed cardiac conditions in patients with high&#x02010;risk cardiovascular comorbidities.<xref rid="jah310323-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref>, <xref rid="jah310323-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref>, <xref rid="jah310323-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref> Although our data did not specifically address the diagnostic process, it is reasonable to speculate that cases with higher risk may not have the positive results of &#x0201c;stress test&#x0201d; immediately recognized, potentially leading to a delay in the initiation of appropriate treatment.</p></sec><sec id="jah310323-sec-0021"><title>Temporal Risk Dynamics of Death in Each Manifestation</title><p>Our data demonstrated the variations in the temporal risk dynamics for death across different manifestations of SHS. Contrary to the mortality risk trends associated with ACS/myocardial injury, HF/LV dysfunction, and other arrhythmia/ECG abnormalities, AF/AFL, and CRA manifestations exhibited distinct temporal risk dynamics, diverging from the general SHS trend.</p><p>In the cases of AF/AFL, a trend of consistent decline in mortality risk over time was observed. This trend suggests that patients diagnosed with AF early on are more prone to exacerbations of preexisting AF or to instances in which AF was first detected at the onset of stroke. Previous studies suggested that the timing of AF detection reflected its subtype.<xref rid="jah310323-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref>, <xref rid="jah310323-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref> Preexisting AF (&#x0201c;known AF&#x0201d;) and AF first detected during the initial stroke presentation (&#x0201c;ECG&#x02010;detected AF&#x0201d;) were associated with a higher AF burden, more severe cardiovascular risk profiles, and poorer outcomes, in contrast with AF diagnosed later through extended ECG monitoring (AF detected after stroke).<xref rid="jah310323-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref>, <xref rid="jah310323-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref> The mortality risk trend observed in our study likely reflects these distinctions, highlighting the impact of early AF detection on patient outcomes.</p><p>CRA presented a unique temporal profile distinctly different from other SHS manifestations. In particular, the median onset of CRA was observed to be 8&#x02009;days after stroke, followed by a downward trend in mortality risk after reaching its peak. Previous experimental studies have suggested a relationship between damage to the central autonomic network, such as the insular cortex, and sudden cardiac death, yet comprehensive clinical data are scarce.<xref rid="jah310323-bib-0026" ref-type="bibr">
<sup>26</sup>
</xref>, <xref rid="jah310323-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref> A study conducted &#x0003e;3 decades ago, examining causes of death among patients with supratentorial infarction, found that sudden deaths typically occurred later, between 2 and 4&#x02009;weeks after stroke onset, as opposed to deaths due to neurological reasons.<xref rid="jah310323-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref> Our findings incorporate into this historical observation and additionally revealed that the mortality risk associated with CRA tends to decrease for events occurring &#x0003e;10&#x02009;days after the stroke onset. While the precise mechanisms underlying this trend remain to be fully understood, it may reflect the stabilization of the patient's overall health following the acute phase. Further research is warranted to explore whether this trend is a consistent finding across different cohorts.</p></sec><sec id="jah310323-sec-0022"><title>Clinical Implications</title><p>Our study highlights the variations of peak incidence across the different manifestations of SHS and the highest mortality risk associated with the timing of SHS development. The progressive increase in mortality risk associated with delays in the onset of SHS underlines the importance of early detection and intervention. Additionally, we have shown the substantial impact on mortality rate posed by ACS/myocardial injury, HF/LV dysfunction, and AF/AFL among the SHS manifestations. These findings highlight the critical need for clinicians to be vigilant in identifying and managing these specific complications. Recognizing the elevated mortality risk associated with these manifestations is of clinical importance.</p></sec><sec id="jah310323-sec-0023"><title>Limitations</title><p>Our study has several limitations. First, the identification of cardiac events within our analysis was based on the documentation of adverse events across various clinical trials included in the VISTA database, rather than direct examination of medical records. This method may lead to underestimation of the true incidence of SHS. This limitation highlights the need for using a more contemporary trial cohort for validation. Second, the retrospective design of our analysis imposed constraints on the availability of certain variables. Specifically, information regarding the anatomic locations of the stroke lesion, which have been shown to influence the incidence of SHS, could not be ascertained.<xref rid="jah310323-bib-0028" ref-type="bibr">
<sup>28</sup>
</xref> Third, the data for our study were predominantly gathered from old clinical trials data, before the widespread adoption of high&#x02010;sensitivity cardiac troponin assays. Given that research using this assay has identified acute myocardial injury in approximately one fifth of patients,<xref rid="jah310323-bib-0029" ref-type="bibr">
<sup>29</sup>
</xref>, <xref rid="jah310323-bib-0030" ref-type="bibr">
<sup>30</sup>
</xref> our data set might not fully capture the incidence of this manifestation due to the era in which the data were collected.</p></sec></sec><sec sec-type="conclusions" id="jah310323-sec-0024"><title>Conclusions</title><p>SHS is associated with a high risk of death, with a greater risk observed with delayed SHS onset. Among the SHS manifestations, ACS/myocardial injury, HF/LV dysfunction, and AF/AFL were associated with the highest risk of death post&#x02010;stroke.</p></sec><sec id="jah310323-sec-0026"><title>Sources of Funding</title><p>This study was funded by the Dowager Countess Eleanor Peel Trust, United Kingdom.</p></sec><sec sec-type="COI-statement" id="jah310323-sec-0027"><title>Disclosures</title><p>Dr Dawson has received speaker fees from AstraZeneca, Bayer, Boehringer Ingelheim, Bristol&#x02010;Myers Squibb, Daiichi Sankyo, Medtronic, and Pfizer, as well as a travel fee from MicroTransponder Inc. He also received an investigator&#x02010;initiated research funding grant from the Stroke Association UK. Dr Lip reports consultant and speaker for BMS/Pfizer, Boehringer Ingelheim, Daiichi&#x02010;Sankyo, and Anthos. No fees are received personally. He is a National Institute for Health and Care Research senior investigator and co&#x02010;principal investigator of the Atrial Fibrillation Integrated Approach in Frail, Multimorbid, and Pollymedicated Older People project on multimorbidity in AF (grant agreement No. 899871), TARGET project on digital twins for personalized management of atrial fibrillation and stroke (grant agreement No. 101136244) and Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) project on artificial intelligence for management of chronic long term conditions (grant agreement No 101080189), which are all funded by the European Union's Horizon Europe Research and Innovation program. The remaining authors have no disclosures to report.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="jah310323-supitem-0001" position="float" content-type="local-data"><caption><p>Tables S1&#x02010;S2</p></caption><media xlink:href="JAH3-13-e036799-s001.pdf"/></supplementary-material></sec></body><back><ack id="jah310323-sec-0025"><title>Acknowledgments</title><p>The authors thank all VISTA collaborators, who contributed previous clinical trial data. The authors also thank ChatGPT (OpenAI) for their support in English language editing of the first draft.</p></ack><ref-list content-type="cited-references" id="jah310323-bibl-0001"><title>References</title><ref id="jah310323-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="jah310323-cit-0001">
<string-name>
<surname>Feigin</surname>
<given-names>VL</given-names>
</string-name>, <string-name>
<surname>Forouzanfar</surname>
<given-names>MH</given-names>
</string-name>, <string-name>
<surname>Krishnamurthi</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Mensah</surname>
<given-names>GA</given-names>
</string-name>, <string-name>
<surname>Connor</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Bennett</surname>
<given-names>DA</given-names>
</string-name>, <string-name>
<surname>Moran</surname>
<given-names>AE</given-names>
</string-name>, <string-name>
<surname>Sacco</surname>
<given-names>RL</given-names>
</string-name>, <string-name>
<surname>Anderson</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Truelsen</surname>
<given-names>T</given-names>
</string-name>, et&#x000a0;al. <article-title>Global and regional burden of stroke during 1990&#x02013;2010: findings from the global burden of disease study 2010</article-title>. <source>Lancet</source>. <year>2014</year>;<volume>383</volume>:<fpage>245</fpage>&#x02013;<lpage>255</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0140-6736(13)61953-4</pub-id>
<pub-id pub-id-type="pmid">24449944</pub-id>
</mixed-citation></ref><ref id="jah310323-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="jah310323-cit-0002">
<string-name>
<surname>Hurd</surname>
<given-names>MD</given-names>
</string-name>, <string-name>
<surname>Goel</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Sakai</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Teramura</surname>
<given-names>Y</given-names>
</string-name>. <article-title>Current status of ischemic stroke treatment: from thrombolysis to potential regenerative medicine</article-title>. <source>Regen Ther</source>. <year>2021</year>;<volume>18</volume>:<fpage>408</fpage>&#x02013;<lpage>417</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.reth.2021.09.009</pub-id>
<pub-id pub-id-type="pmid">34722837</pub-id>
</mixed-citation></ref><ref id="jah310323-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="jah310323-cit-0003">
<string-name>
<surname>Prosser</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>MacGregor</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Lees</surname>
<given-names>KR</given-names>
</string-name>, <string-name>
<surname>Diener</surname>
<given-names>HC</given-names>
</string-name>, <string-name>
<surname>Hacke</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Davis</surname>
<given-names>S</given-names>
</string-name>. <article-title>Predictors of early cardiac morbidity and mortality after ischemic stroke</article-title>. <source>Stroke</source>. <year>2007</year>;<volume>38</volume>:<fpage>2295</fpage>&#x02013;<lpage>2302</lpage>. doi: <pub-id pub-id-type="doi">10.1161/STROKEAHA.106.471813</pub-id>
<pub-id pub-id-type="pmid">17569877</pub-id>
</mixed-citation></ref><ref id="jah310323-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="jah310323-cit-0004">
<string-name>
<surname>Scheitz</surname>
<given-names>JF</given-names>
</string-name>, <string-name>
<surname>Nolte</surname>
<given-names>CH</given-names>
</string-name>, <string-name>
<surname>Doehner</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Hachinski</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Endres</surname>
<given-names>M</given-names>
</string-name>. <article-title>Stroke&#x02013;heart syndrome: clinical presentation and underlying mechanisms</article-title>. <source>Lancet Neurol</source>. <year>2018</year>;<volume>17</volume>:<fpage>1109</fpage>&#x02013;<lpage>1120</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S1474-4422(18)30336-3</pub-id>
<pub-id pub-id-type="pmid">30509695</pub-id>
</mixed-citation></ref><ref id="jah310323-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="jah310323-cit-0005">
<string-name>
<surname>Sposato</surname>
<given-names>LA</given-names>
</string-name>, <string-name>
<surname>Lam</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Allen</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Shariff</surname>
<given-names>SZ</given-names>
</string-name>, <string-name>
<surname>Saposnik</surname>
<given-names>G</given-names>
</string-name>. <article-title>First&#x02010;ever ischemic stroke and incident major adverse cardiovascular events in 93 627 older women and men</article-title>. <source>Stroke</source>. <year>2020</year>;<volume>51</volume>:<fpage>387</fpage>&#x02013;<lpage>394</lpage>. doi: <pub-id pub-id-type="doi">10.1161/STROKEAHA.119.028066</pub-id>
<pub-id pub-id-type="pmid">31914883</pub-id>
</mixed-citation></ref><ref id="jah310323-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="jah310323-cit-0006">
<string-name>
<surname>Scheitz</surname>
<given-names>JF</given-names>
</string-name>, <string-name>
<surname>Sposato</surname>
<given-names>LA</given-names>
</string-name>, <string-name>
<surname>Schulz&#x02010;Menger</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Nolte</surname>
<given-names>CH</given-names>
</string-name>, <string-name>
<surname>Backs</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Endres</surname>
<given-names>M</given-names>
</string-name>. <article-title>Stroke&#x02013;heart syndrome: recent advances and challenges</article-title>. <source>J Am Heart Assoc</source>. <year>2022</year>;<volume>11</volume>:<elocation-id>e026528</elocation-id>. doi: <pub-id pub-id-type="doi">10.1161/JAHA.122.026528</pub-id>
<pub-id pub-id-type="pmid">36056731</pub-id>
</mixed-citation></ref><ref id="jah310323-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="jah310323-cit-0007">
<string-name>
<surname>Sposato</surname>
<given-names>LA</given-names>
</string-name>, <string-name>
<surname>Hilz</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Aspberg</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Murthy</surname>
<given-names>SB</given-names>
</string-name>, <string-name>
<surname>Bahit</surname>
<given-names>MC</given-names>
</string-name>, <string-name>
<surname>Hsieh</surname>
<given-names>CY</given-names>
</string-name>, <string-name>
<surname>Sheppard</surname>
<given-names>MN</given-names>
</string-name>, <string-name>
<surname>Scheitz</surname>
<given-names>JF</given-names>
</string-name>. <article-title>Post&#x02010;stroke cardiovascular complications and neurogenic cardiac injury: JACC state&#x02010;of&#x02010;the&#x02010;art review</article-title>. <source>J Am Coll Cardiol</source>. <year>2020</year>;<volume>76</volume>:<fpage>2768</fpage>&#x02013;<lpage>2785</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jacc.2020.10.009</pub-id>
<pub-id pub-id-type="pmid">33272372</pub-id>
</mixed-citation></ref><ref id="jah310323-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="jah310323-cit-0008">
<string-name>
<surname>Buckley</surname>
<given-names>BJR</given-names>
</string-name>, <string-name>
<surname>Harrison</surname>
<given-names>SL</given-names>
</string-name>, <string-name>
<surname>Lane</surname>
<given-names>DA</given-names>
</string-name>, <string-name>
<surname>Hill</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Lip</surname>
<given-names>GYH</given-names>
</string-name>. <article-title>Stroke&#x02013;heart syndrome: mechanisms, risk factors, and adverse cardiovascular events</article-title>. <source>Eur J Prev Cardiol</source>. <year>2023</year>;<volume>44</volume>:<fpage>1</fpage>&#x02013;<lpage>4</lpage>.</mixed-citation></ref><ref id="jah310323-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="jah310323-cit-0009">
<string-name>
<surname>Bucci</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Sagris</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Harrison</surname>
<given-names>SL</given-names>
</string-name>, <string-name>
<surname>Underhill</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Pastori</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Ntaios</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>McDowell</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Buckley</surname>
<given-names>BJR</given-names>
</string-name>, <string-name>
<surname>Lip</surname>
<given-names>GYH</given-names>
</string-name>. <article-title>C&#x02010;reactive protein levels are associated with early cardiac complications or death in patients with acute ischemic stroke: a propensity&#x02010;matched analysis of a global federated health from the TriNetX network</article-title>. <source>Intern Emerg Med</source>. <year>2023</year>;<volume>18</volume>:<fpage>1329</fpage>&#x02013;<lpage>1336</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s11739-023-03280-1</pub-id>
<pub-id pub-id-type="pmid">37119383</pub-id>
</mixed-citation></ref><ref id="jah310323-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="jah310323-cit-0010">
<string-name>
<surname>Litmeier</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Meinel</surname>
<given-names>TR</given-names>
</string-name>, <string-name>
<surname>von Rennenberg</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Kniepert</surname>
<given-names>JU</given-names>
</string-name>, <string-name>
<surname>Audebert</surname>
<given-names>HJ</given-names>
</string-name>, <string-name>
<surname>Endres</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Jung</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Scheitz</surname>
<given-names>JF</given-names>
</string-name>, <string-name>
<surname>Nolte</surname>
<given-names>CH</given-names>
</string-name>. <article-title>Coronary angiography in acute ischemic stroke patients: frequency and determinants of pathological findings in a multicenter cohort study</article-title>. <source>J Neurol</source>. <year>2022</year>;<volume>269</volume>:<fpage>3745</fpage>&#x02013;<lpage>3751</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00415-022-11001-5</pub-id>
<pub-id pub-id-type="pmid">35182178</pub-id>
</mixed-citation></ref><ref id="jah310323-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="jah310323-cit-0011">
<string-name>
<surname>Gattringer</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Niederkorn</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Seyfang</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Seifert&#x02010;Held</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Simmet</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Ferrari</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Lang</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Brainin</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Willeit</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Fazekas</surname>
<given-names>F</given-names>
</string-name>, et&#x000a0;al. <article-title>Myocardial infarction as a complication in acute stroke: results from the Austrian stroke unit registry</article-title>. <source>Cerebrovasc Dis</source>. <year>2014</year>;<volume>37</volume>:<fpage>147</fpage>&#x02013;<lpage>152</lpage>. doi: <pub-id pub-id-type="doi">10.1159/000357799</pub-id>
<pub-id pub-id-type="pmid">24481543</pub-id>
</mixed-citation></ref><ref id="jah310323-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="jah310323-cit-0012">
<string-name>
<surname>Ali</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Bath</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Brady</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Davis</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Diener</surname>
<given-names>H&#x02010;C</given-names>
</string-name>, <string-name>
<surname>Donnan</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Fisher</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Hacke</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Hanley</surname>
<given-names>DF</given-names>
</string-name>, <string-name>
<surname>Luby</surname>
<given-names>M</given-names>
</string-name>, et&#x000a0;al. <article-title>Development, expansion, and use of a stroke clinical trials resource for novel exploratory analyses</article-title>. <source>Int J Stroke</source>. <year>2012</year>;<volume>7</volume>:<fpage>133</fpage>&#x02013;<lpage>138</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.1747-4949.2011.00735.x</pub-id>
<pub-id pub-id-type="pmid">22264365</pub-id>
</mixed-citation></ref><ref id="jah310323-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="jah310323-cit-0013">
<string-name>
<surname>Ali</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Bath</surname>
<given-names>PMW</given-names>
</string-name>, <string-name>
<surname>Curram</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Davis</surname>
<given-names>SM</given-names>
</string-name>, <string-name>
<surname>Diener</surname>
<given-names>H&#x02010;C</given-names>
</string-name>, <string-name>
<surname>Donnan</surname>
<given-names>GA</given-names>
</string-name>, <string-name>
<surname>Fisher</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Gregson</surname>
<given-names>BA</given-names>
</string-name>, <string-name>
<surname>Grotta</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Hacke</surname>
<given-names>W</given-names>
</string-name>, et&#x000a0;al. <article-title>The virtual international stroke trials archive</article-title>. <source>Stroke</source>. <year>2007</year>;<volume>38</volume>:<fpage>1905</fpage>&#x02013;<lpage>1910</lpage>. doi: <pub-id pub-id-type="doi">10.1161/STROKEAHA.106.473579</pub-id>
<pub-id pub-id-type="pmid">17446430</pub-id>
</mixed-citation></ref><ref id="jah310323-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="jah310323-cit-0014">
<string-name>
<surname>von Elm</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Altman</surname>
<given-names>DG</given-names>
</string-name>, <string-name>
<surname>Egger</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Pocock</surname>
<given-names>SJ</given-names>
</string-name>, <string-name>
<surname>G&#x000f8;tzsche</surname>
<given-names>PC</given-names>
</string-name>, <string-name>
<surname>Vandenbroucke</surname>
<given-names>JP</given-names>
</string-name>. <article-title>The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies</article-title>. <source>J Clin Epidemiol</source>. <year>2008</year>;<volume>61</volume>:<fpage>344</fpage>&#x02013;<lpage>349</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jclinepi.2007.11.008</pub-id>
<pub-id pub-id-type="pmid">18313558</pub-id>
</mixed-citation></ref><ref id="jah310323-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="jah310323-cit-0015">
<string-name>
<surname>Orlandi</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Fanucchi</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Strata</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Pataleo</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Landucci Pellegrini</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Prontera</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Martini</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Murri</surname>
<given-names>L</given-names>
</string-name>. <article-title>Transient autonomic nervous system dysfunction during hyperacute stroke</article-title>. <source>Acta Neurol Scand</source>. <year>2000</year>;<volume>102</volume>:<fpage>317</fpage>&#x02013;<lpage>321</lpage>. doi: <pub-id pub-id-type="doi">10.1034/j.1600-0404.2000.102005317.x</pub-id>
<pub-id pub-id-type="pmid">11083509</pub-id>
</mixed-citation></ref><ref id="jah310323-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="jah310323-cit-0016">
<string-name>
<surname>Tatschl</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>St&#x000f6;llberger</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Matz</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Yilmaz</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Eckhardt</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Nowotny</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Dachenhausen</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Brainin</surname>
<given-names>M</given-names>
</string-name>. <article-title>Insular involvement is associated with QT prolongation: ECG abnormalities in patients with acute stroke</article-title>. <source>Cerebrovasc Dis</source>. <year>2006</year>;<volume>21</volume>:<fpage>47</fpage>&#x02013;<lpage>53</lpage>. doi: <pub-id pub-id-type="doi">10.1159/000089594</pub-id>
<pub-id pub-id-type="pmid">16282690</pub-id>
</mixed-citation></ref><ref id="jah310323-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="jah310323-cit-0017">
<string-name>
<surname>Jung</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>JG</given-names>
</string-name>, <string-name>
<surname>Bin</surname>
<given-names>KJ</given-names>
</string-name>, <string-name>
<surname>Cho</surname>
<given-names>KH</given-names>
</string-name>, <string-name>
<surname>Yu</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Oh</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>YH</given-names>
</string-name>, <string-name>
<surname>Choi</surname>
<given-names>JY</given-names>
</string-name>, <string-name>
<surname>Seo</surname>
<given-names>WK</given-names>
</string-name>. <article-title>Takotsubo&#x02010;like myocardial dysfunction in ischemic stroke: a hospital&#x02010;based registry and systematic literature review</article-title>. <source>Stroke</source>. <year>2016</year>;<volume>47</volume>:<fpage>2729</fpage>&#x02013;<lpage>2736</lpage>. doi: <pub-id pub-id-type="doi">10.1161/STROKEAHA.116.014304</pub-id>
<pub-id pub-id-type="pmid">27729583</pub-id>
</mixed-citation></ref><ref id="jah310323-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="jah310323-cit-0018">
<string-name>
<surname>Liao</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>O'Donnell</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Silver</surname>
<given-names>FL</given-names>
</string-name>, <string-name>
<surname>Thiruchelvam</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Saposnik</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Fang</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Gould</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Mohamed</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Kapral</surname>
<given-names>MK</given-names>
</string-name>. <article-title>In&#x02010;hospital myocardial infarction following acute ischaemic stroke: an observational study</article-title>. <source>Eur J Neurol</source>. <year>2009</year>;<volume>16</volume>:<fpage>1035</fpage>&#x02013;<lpage>1040</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.1468-1331.2009.02647.x</pub-id>
<pub-id pub-id-type="pmid">19614964</pub-id>
</mixed-citation></ref><ref id="jah310323-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="jah310323-cit-0019">
<string-name>
<surname>Yoshimura</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Toyoda</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Ohara</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Nagasawa</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Ohtani</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Kuwashiro</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Naritomi</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Minematsu</surname>
<given-names>K</given-names>
</string-name>. <article-title>Takotsubo cardiomyopathy in acute ischemic stroke</article-title>. <source>Ann Neurol</source>. <year>2008</year>;<volume>64</volume>:<fpage>547</fpage>&#x02013;<lpage>554</lpage>. doi: <pub-id pub-id-type="doi">10.1002/ana.21459</pub-id>
<pub-id pub-id-type="pmid">18688801</pub-id>
</mixed-citation></ref><ref id="jah310323-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="jah310323-cit-0020">
<string-name>
<surname>Scheitz</surname>
<given-names>JF</given-names>
</string-name>, <string-name>
<surname>Nolte</surname>
<given-names>CH</given-names>
</string-name>, <string-name>
<surname>Laufs</surname>
<given-names>U</given-names>
</string-name>, <string-name>
<surname>Endres</surname>
<given-names>M</given-names>
</string-name>. <article-title>Application and interpretation of high&#x02010;sensitivity cardiac troponin assays in patients with acute ischemic stroke</article-title>. <source>Stroke</source>. <year>2015</year>;<volume>46</volume>:<fpage>1132</fpage>&#x02013;<lpage>1140</lpage>. doi: <pub-id pub-id-type="doi">10.1161/STROKEAHA.114.007858</pub-id>
<pub-id pub-id-type="pmid">25737317</pub-id>
</mixed-citation></ref><ref id="jah310323-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="jah310323-cit-0021">
<string-name>
<surname>Oppenheimer</surname>
<given-names>SM</given-names>
</string-name>, <string-name>
<surname>Gelb</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Girvin</surname>
<given-names>JP</given-names>
</string-name>, <string-name>
<surname>Hachinski</surname>
<given-names>VC</given-names>
</string-name>. <article-title>Cardiovascular effects of human insular cortex stimulation</article-title>. <source>Neurology</source>. <year>1992</year>;<volume>42</volume>:<fpage>1727</fpage>&#x02013;<lpage>1732</lpage>. doi: <pub-id pub-id-type="doi">10.1212/WNL.42.9.1727</pub-id>
<pub-id pub-id-type="pmid">1513461</pub-id>
</mixed-citation></ref><ref id="jah310323-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="jah310323-cit-0022">
<string-name>
<surname>Sposato</surname>
<given-names>LA</given-names>
</string-name>, <string-name>
<surname>Chaturvedi</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Hsieh</surname>
<given-names>CY</given-names>
</string-name>, <string-name>
<surname>Morillo</surname>
<given-names>CA</given-names>
</string-name>, <string-name>
<surname>Kamel</surname>
<given-names>H</given-names>
</string-name>. <article-title>Atrial fibrillation detected after stroke and transient ischemic attack: a novel clinical concept challenging current views</article-title>. <source>Stroke</source>. <year>2022</year>;<volume>29</volume>:<fpage>E94</fpage>&#x02013;<lpage>E103</lpage>. doi: <pub-id pub-id-type="doi">10.1161/STROKEAHA.121.034777</pub-id>
</mixed-citation></ref><ref id="jah310323-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="jah310323-cit-0023">
<string-name>
<surname>Sposato</surname>
<given-names>LA</given-names>
</string-name>, <string-name>
<surname>Field</surname>
<given-names>TS</given-names>
</string-name>, <string-name>
<surname>Schnabel</surname>
<given-names>RB</given-names>
</string-name>, <string-name>
<surname>Wachter</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Andrade</surname>
<given-names>JG</given-names>
</string-name>, <string-name>
<surname>Hill</surname>
<given-names>MD</given-names>
</string-name>. <article-title>Towards a new classification of atrial fibrillation detected after a stroke or a transient ischaemic attack</article-title>. <source>Lancet Neurol</source>. <year>2023</year>;<volume>23</volume>:<fpage>110</fpage>&#x02013;<lpage>122</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S1474-4422(23)00326-5</pub-id>
<pub-id pub-id-type="pmid">37839436</pub-id>
</mixed-citation></ref><ref id="jah310323-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="jah310323-cit-0024">
<string-name>
<surname>Alvarado&#x02010;Bola&#x000f1;os</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Ayan</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Khaw</surname>
<given-names>AV</given-names>
</string-name>, <string-name>
<surname>Mai</surname>
<given-names>LM</given-names>
</string-name>, <string-name>
<surname>Mandzia</surname>
<given-names>JL</given-names>
</string-name>, <string-name>
<surname>Bogiatzi</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Mrkobrada</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Bres&#x02010;Bullrich</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Fleming</surname>
<given-names>LA</given-names>
</string-name>, <string-name>
<surname>Lippert</surname>
<given-names>C</given-names>
</string-name>, et&#x000a0;al. <article-title>Differences in stroke recurrence risk between atrial fibrillation detected on ECG and 14&#x02010;day cardiac monitoring</article-title>. <source>Stroke</source>. <year>2023</year>;<volume>54</volume>:<fpage>2022</fpage>&#x02013;<lpage>2030</lpage>. doi: <pub-id pub-id-type="doi">10.1161/STROKEAHA.123.043672</pub-id>
<pub-id pub-id-type="pmid">37377007</pub-id>
</mixed-citation></ref><ref id="jah310323-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="jah310323-cit-0025">
<string-name>
<surname>Sposato</surname>
<given-names>LA</given-names>
</string-name>, <string-name>
<surname>Cipriano</surname>
<given-names>LE</given-names>
</string-name>, <string-name>
<surname>Saposnik</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Vargas</surname>
<given-names>ER</given-names>
</string-name>, <string-name>
<surname>Riccio</surname>
<given-names>PM</given-names>
</string-name>, <string-name>
<surname>Hachinski</surname>
<given-names>V</given-names>
</string-name>. <article-title>Diagnosis of atrial fibrillation after stroke and transient ischaemic attack: a systematic review and meta&#x02010;analysis</article-title>. <source>Lancet Neurol</source>. <year>2015</year>;<volume>14</volume>:<fpage>377</fpage>&#x02013;<lpage>387</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S1474-4422(15)70027-X</pub-id>
<pub-id pub-id-type="pmid">25748102</pub-id>
</mixed-citation></ref><ref id="jah310323-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="jah310323-cit-0026">
<string-name>
<surname>Tokg&#x000f6;zoglu</surname>
<given-names>SL</given-names>
</string-name>, <string-name>
<surname>Batur</surname>
<given-names>MK</given-names>
</string-name>, <string-name>
<surname>Top&#x000e7;uoglu</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Saribas</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Kes</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Oto</surname>
<given-names>A</given-names>
</string-name>. <article-title>Effects of stroke localization on cardiac autonomic balance and sudden death</article-title>. <source>Stroke</source>. <year>1999</year>;<volume>30</volume>:<fpage>1307</fpage>&#x02013;<lpage>1311</lpage>. doi: <pub-id pub-id-type="doi">10.1161/01.STR.30.7.1307</pub-id>
<pub-id pub-id-type="pmid">10390300</pub-id>
</mixed-citation></ref><ref id="jah310323-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="jah310323-cit-0027">
<string-name>
<surname>Silver</surname>
<given-names>FL</given-names>
</string-name>, <string-name>
<surname>Norris</surname>
<given-names>JW</given-names>
</string-name>, <string-name>
<surname>Lewis</surname>
<given-names>AJ</given-names>
</string-name>, <string-name>
<surname>Hachinski</surname>
<given-names>VC</given-names>
</string-name>. <article-title>Early mortality following stroke: a prospective review</article-title>. <source>Stroke</source>. <year>1984</year>;<volume>15</volume>:<fpage>492</fpage>&#x02013;<lpage>496</lpage>. doi: <pub-id pub-id-type="doi">10.1161/01.STR.15.3.492</pub-id>
<pub-id pub-id-type="pmid">6729878</pub-id>
</mixed-citation></ref><ref id="jah310323-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="jah310323-cit-0028">
<string-name>
<surname>Scheitz</surname>
<given-names>JF</given-names>
</string-name>, <string-name>
<surname>Stengl</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Nolte</surname>
<given-names>CH</given-names>
</string-name>, <string-name>
<surname>Landmesser</surname>
<given-names>U</given-names>
</string-name>, <string-name>
<surname>Endres</surname>
<given-names>M</given-names>
</string-name>. <article-title>Neurological update: use of cardiac troponin in patients with stroke</article-title>. <source>J Neurol</source>. <year>2021</year>;<volume>268</volume>:<fpage>2284</fpage>&#x02013;<lpage>2292</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00415-020-10349-w</pub-id>
<pub-id pub-id-type="pmid">33372247</pub-id>
</mixed-citation></ref><ref id="jah310323-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="jah310323-cit-0029">
<string-name>
<surname>Stengl</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Ganeshan</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Hellwig</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Klammer</surname>
<given-names>MG</given-names>
</string-name>, <string-name>
<surname>von Rennenberg</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>B&#x000f6;hme</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Audebert</surname>
<given-names>HJ</given-names>
</string-name>, <string-name>
<surname>Nolte</surname>
<given-names>CH</given-names>
</string-name>, <string-name>
<surname>Endres</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Scheitz</surname>
<given-names>JF</given-names>
</string-name>. <article-title>Frequency, associated variables, and outcomes of acute myocardial injury according to the fourth universal definition of myocardial infarction in patients with acute ischemic stroke</article-title>. <source>Eur Stroke J</source>. <year>2022</year>;<volume>7</volume>:<fpage>413</fpage>&#x02013;<lpage>420</lpage>. doi: <pub-id pub-id-type="doi">10.1177/23969873221120159</pub-id>
<pub-id pub-id-type="pmid">36478763</pub-id>
</mixed-citation></ref><ref id="jah310323-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="jah310323-cit-0030">
<string-name>
<surname>Scheitz</surname>
<given-names>JF</given-names>
</string-name>, <string-name>
<surname>Mochmann</surname>
<given-names>HC</given-names>
</string-name>, <string-name>
<surname>Erdur</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>T&#x000fc;t&#x000fc;nc&#x000fc;</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Haeusler</surname>
<given-names>KG</given-names>
</string-name>, <string-name>
<surname>Grittner</surname>
<given-names>U</given-names>
</string-name>, <string-name>
<surname>Laufs</surname>
<given-names>U</given-names>
</string-name>, <string-name>
<surname>Endres</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Nolte</surname>
<given-names>CH</given-names>
</string-name>. <article-title>Prognostic relevance of cardiac troponin T levels and their dynamic changes measured with a high&#x02010;sensitivity assay in acute ischaemic stroke: analyses from the TRELAS cohort</article-title>. <source>Int J Cardiol</source>. <year>2014</year>;<volume>177</volume>:<fpage>886</fpage>&#x02013;<lpage>893</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ijcard.2014.10.036</pub-id>
<pub-id pub-id-type="pmid">25453407</pub-id>
</mixed-citation></ref></ref-list><app-group><app id="jah310323-app-0001" content-type="Appendix"><sec sec-type="opening-section" id="jah310323-sec-0028"><title>VISTA&#x02010;Acute Steering Committee members</title><p>K. R. Lees (Chair), A. Alexandrov, P. M. Bath, E. Bluhmki, N. Bornstein, C. Chen, L. Claesson, J. Curram, S. M. Davis, H&#x02010;C. Diener, G. Donnan, M. Fisher, M. Ginsberg, B. Gregson, J. Grotta, W. Hacke, M. G. Hennerici, M. Hommel, M. Kaste, P. Lyden, J. Marler, K. Muir, C. Roffe, R. Sacco, A. Shuaib, P. Teal, N. Venketasubramanian, N. G. Wahlgren, and S. Warach.</p></sec></app></app-group></back></article>